Completed
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells)
NCT04640402
- Conditions
- COVID-19, Coronaviridae Infections, Coronavirus Infections, +9 more
- Locations
-
- Jiangsu Provincial Center for Diseases Control and Prevention Nanjing, Jiangsu, China